Browsing by Author "Elizabeth Mayne"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Frequency kinetics and determinants of viable SARSCoV2 in bioaerosols from ambulatory COVID19 patients infected with the Beta Delta or Omicron variants(NATURE PUBLISHING GROUP) S Jaumdally; M Tomasicchio; A Pooran; A Esmail; Elizabeth Mayne; Penelope Moore; E et alItem SARSCoV2 Antigens Expressed in Plants Detect Antibody Responses in COVID19 PatientsM Makatsa; M Tincho; J Wendoh; S Ismail; Anura David; Maemu Gededzha; Nakampe Mampeule; Ian Sanne; Wendy Stevens; Lesley Scott; Elizabeth Mayne; E et alItem The Novel Coronavirus and Haemostatic abnormalities pathophysiology clinical manifesttations and treatment recommendationsSusan Louw; Barry Jacobson; Elizabeth Mayne; Tracey WiggillThe COVID-19 pandemic, caused by the SARS-C0V-2 virus, was initially considered and managed in a similar manner to the previous SARS epidemic as they are both caused by coronaviruses. What has now become apparent is that a major cause of morbidity and mortality in COVID-19 is abnormal thrombosis. This thrombosis occurs on a macro- and microvascular level and is unique to this disease. The virus has been demonstrated in the endothelium of the pulmonary alveoli and as such is thought to contribute to the devastating respiratory complications encountered. D-dimer concentrations are frequently raised in COVID to levels not frequently seen previously. The optimal anticoagulation treatment in COVID remains to be determined, and the myriad of pathophysiologic effects caused by this virus in the human host have also yet to be fully elucidated.